Rosuvastatin calcium price index

Rosuvastatin calcium price December 2025 and outlook (see chart below)

• India:US$176.14/KG, -0.2% down

Business Analytiq assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness, or timeliness.

Rosuvastatin calcium price index

This post is a summary of the Rosuvastatin calcium price developments. The price developments of Rosuvastatin calcium are expressed in US$ prices converted FX rates applicable at the time when the price was valid. Rosuvastatin calcium price index developments are calculated from multiple separate sources of data to ensure statistical accuracy.

The outlook for Rosuvastatin calcium prices is generated from different inputs including:

• Very recent price developments of immediate cost drivers of Rosuvastatin calcium prices
• Recent price developments of underlying feedstocks which drive the price of Rosuvastatin calcium
• Market futures for both cost drives and feedstocks of Rosuvastatin calcium prices
• Adjustment of current supply/demand imbalances in the Rosuvastatin calcium market
• Longer term trends in likely demand conditions

What is Rosuvastatin Calcium and what is it used for

Rosuvastatin Calcium is a lipid‐lowering medication belonging to the statin class, which works by inhibiting the enzyme HMG‑CoA reductase in the liver.} It is used to reduce levels of “bad” cholesterol (low‑density lipoprotein, LDL) and triglycerides, and to increase levels of “good” cholesterol (high‑density lipoprotein, HDL). It is prescribed for adults (and in some cases children) to treat primary hypercholesterolaemia, mixed dyslipidaemia, and to help prevent cardiovascular events such as heart attack or stroke in patients at high risk.

How is Rosuvastatin Calcium produced and supplied

The active pharmaceutical ingredient (API) of rosuvastatin calcium is manufactured in pharmaceutical production facilities (often in Asia‑Pacific and Europe) and then formulated into oral dosage forms (tablets or capsules) for dispensing to patients. For example, it may be available as a once‑daily tablet, in various strengths. The process involves high‑purity API production (e.g., >99 % grade) and then formulation and packaging by pharmaceutical companies (brand and generic). After production, the finished products are distributed globally through pharmacies, hospitals and clinics, subject to regulatory approvals. Because of its wide generic use, many manufacturers produce rosuvastatin calcium or its equivalents.

How large is the global market for Rosuvastatin Calcium and where is it produced

The global market for rosuvastatin calcium (API and finished formulations) is valued in the hundreds of millions of U.S. dollars, and is projected to grow at a moderate compound annual growth rate (CAGR). One estimate puts the market at approximately **USD 0.62 billion in 2025**, projected to reach **USD 0.98 billion by 2034**, with a CAGR around **5.25%**. Other sources give a market size of about USD 0.501 billion in 2024 with growth to ~USD 0.693 billion by 2032 (CAGR ~4.3%) in certain segments.Production is concentrated in regions such as Asia‑Pacific, where one source says Asia‑Pacific accounted for about 60% of global API production in 2023, led by countries such as China and India. Europe is a major consumer region (approximately 34% of global consumption) and also a significant production and export region; China held around 28% production share in one estimate. The major companies involved include AstraZeneca (which developed the original branded product under the name Crestor), as well as generic manufacturers such as MSN Laboratories, Changzhou Pharmaceutical Factory and others. }